Biological activity of a transforming growth factor-alpha-Pseudomonas exotoxin fusion protein in vitro and in vivo |
| |
Authors: | David C. Heimbrook Steven M. Stirdivant Janet D. Ahern Nancy L. Balishin Denis R. Patrick Gwynneth M. Edwards Deborah Defeo-Jones David J. FitzGerald Ira Pastan Allen Oliff |
| |
Affiliation: | (1) Department of Cancer Research, Merck Sharp and Dohme Research Laboratories, 19486 West Point, PA, USA;(2) Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD |
| |
Abstract: | Summary Transforming growth factor-alpha (TGF)-pseudomonas exotoxin-40 (PE40) is a chimeric protein consisting of an N-terminal TGF domain fused to a C-terminal 40-kDa segment of the pseudomonas exotoxin A protein. TGF-PE40 exhibits the receptor binding activity of TGF and the cell killing activity of PE40. In the current study, we report that a modified TGF-PE40 derivative significantly prolongs the survival of nude mice bearing tumors derived from cell lines which express the epidermal growth factor receptor (EGFR). In addition, the therapeutic benefit of this protein is mediated by specific binding to the EGF receptor. These results indicate that a therapeutic window exists in vivo for the use of some growth factor-toxin fusion proteins as anticancer agents. |
| |
Keywords: | Epidermal growth factor Exotoxin Cancer |
本文献已被 SpringerLink 等数据库收录! |